Algernon Pharmaceuticals Inc
CNSX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hangzhou Zhongya Machinery Co Ltd
SZSE:300512
|
CN |
|
Recticel NV
LSE:0NHV
|
BE |
|
Aarti Surfactants Ltd
NSE:AARTISURF
|
IN |
|
Z
|
Zhejiang Kaier New Materials Co Ltd
SZSE:300234
|
CN |
|
Petroleo Brasileiro SA Petrobras
BOVESPA:PETR4
|
BR |
|
Thoughtworks Holding Inc
NASDAQ:TWKS
|
US |
|
Z
|
Zhong Ao Home Group Ltd
HKEX:1538
|
CN |
|
Jiangxi Hengda Hi-Tech Co Ltd
SZSE:002591
|
CN |
Algernon Pharmaceuticals Inc
Stock-Based Compensation
Algernon Pharmaceuticals Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Algernon Pharmaceuticals Inc
CNSX:AGN
|
Stock-Based Compensation
CA$196.6k
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Stock-Based Compensation
$5.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Perimeter Medical Imaging AI Inc
XTSX:PINK
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
VentriPoint Diagnostics Ltd
XTSX:VPT
|
Stock-Based Compensation
CA$559.8k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Stock-Based Compensation
CA$697.7k
|
CAGR 3-Years
62%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Stock-Based Compensation
$672k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
2%
|
|
Algernon Pharmaceuticals Inc
Glance View
Algernon Pharmaceuticals Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).
See Also
What is Algernon Pharmaceuticals Inc's Stock-Based Compensation?
Stock-Based Compensation
196.6k
CAD
Based on the financial report for Nov 30, 2025, Algernon Pharmaceuticals Inc's Stock-Based Compensation amounts to 196.6k CAD.
What is Algernon Pharmaceuticals Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-44%
The average annual Stock-Based Compensation growth rates for Algernon Pharmaceuticals Inc have been -44% over the past three years , -44% over the past five years .
